მენოპაუზალური ჰორმონალური თერაპიის (მ.ჰ.თ.) ძირითადი ასპექტები
DOI:
https://doi.org/10.52340/jecm.2023.03.01საკვანძო სიტყვები:
Menopausal hormonal therapy (M.H.T.), Drospirenone, Endometrium, menopauseანოტაცია
განხილულია მ.ჰ.თ.-ის სხვადასხვა ასპექტები. ჩანაცვლებითი ჰორმონალური თერაპიის ეს სახეობა იწვევს სუბიექტური ჩივილების კუპირებას, აგრეთვე გულ-სისხლძარღვთა დაავადებების და ოსტეოპოროზის პროფილაქტიკას. ცალკეულ შემთხვევებში მ.ჰ.თ.-ს დანიშვნა ეყრდნობა სარგებელი/რისკის შეფარდების ზუსტ შეფასებას. რეკომენდებულია ჰორმონების დაბალი, ეფექტური დოზები (Э – 0,5მგ/დროსპირენონი – 0,25მგ) უწყვეტ რეჟიმში, პერორალური მიღების გზით.
Downloads
წყაროები
Adamyan L.V., Melnikova N.S., et al. Pathology of the endometrium in the elderly and senile age (screening study). Archive of Pathology. 2013; 75(6): 32-8. (In Russian).
Aksel E.M. Morbidity and mortality from malignant neoplasms of the female reproductive system in Russia. Oncogynecologia. 2015; (1): 4-13. (In Russian).
Baber R.J., Panay N., et al. JMS Writing Group. 2016 JMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.
Canonico M., Oger E., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840-5.
Canonico M., Faurnier A., et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010; 30(2): 340-5.
Caprio M., Zennaro M.C., et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric. 2008; 11(3): 258-64.
Carugno J. Clinical management of vaginal bleeding in postmenopausal women 2020. Climacteric. 2020; Apr 1:1-7.
Chlebowski R.T., Anderson G.L., et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010; 304(15): 1684-92.
Chlebowski R.T., Luo J., et al. Weight loss and breast cancer incidence in postmenopausal women. Cancer. 2019; 125(2): 205-12.
Colombo N., Preti E., et al. ESMO Guidelines Working Group. Endometrial cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(6):33-8.
Dinger J. Bardenheuer K., et al. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016; 19(4): 349-56.
Gambacciani M., Cagnacci A., et al. Hormone replacement therapy and prevention of chronic conditions. Climacteric. 2019; 22(3): 303-6.
Gass M.L., Maki P.M., et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015; 22(7): 685-6.
Gerlinger C., Gude K., et al. Recommendation for the collection and analysis of endometrial biopsies for hormone therapies. Climacteric. 2012; 15: 52-8.
Gerlinger C., Gude K., et al. 0,5 vs. 1,0mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric. 2015; 18(4): 512-7.
Grigoryan O.R. Efficacy and safety of the use of ultra-low doses of drospirenone and 17β - estradiol in postmenopausal women. Meta-analysis. Medical Advice. 2018; (7): 126-32.
Hodis H.N., Sarrel P.M. Menopausal hormone therapy and breast cancer: What is the evidence from randomized trials? Climacteric. 2018; 21(6): 521-8.
Hunter M.S. The Women’s Health Questionnaire: a measure of mid-aged women’s perceptions of their emotional and physical health. Psychol. Health. 1992; 7: 45-54.
Joseph J.J., Echouffo Tcheugui J.B., et al. Renin-angiotensin-aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA. J. Am. Heart Assoc. 2019; 7(17): e009890.
Menopauzal’naya gormonoterapya I sokhranenie zdorov’ya zhenshchin v zrelom vozraste. Klinicheskie rekomendatsii (protocol lecheniya). Pis’mo Ministerstva zdorovookhraneniya Rossiiskoi Feretatsii ot 2 Oktober 2015. N15-4/10/2-5804. (In Russian).
Renoux C., Dell’Aniello S., et al. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J. Thromb. Haemost. 2010; 8(5): 979-86.
Rossouw J.E., Anderson G.I. et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33.
Rubin R. Postmenopausal women with a „normal“ BMI might be overweight or even obese. JAMA. 2018; 319(12): 1185-7.
Schindler A.E., Campagnoli C., et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80.
Slopien R., Wender-Ozegowska E., et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018; 117: 6-10.
Straczek C., Oger E., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112(22): 3495-500.
Sturdee D.W., Pines A.: International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14: 302-20.
Trabert B., Wentzensen N., et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int. J. Cancer. 2013; 132(2): 417-26.
Vinogradova Y., Coupland C., et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q-Research and CPRD databases. BMJ. 2019; 364: K4810.
Wright A.K., Kontopanteliz E., et al. Cardiovascular risk and risk factor management in type 2 diabetes mellitus. Circulation. 2019; 139(24): 2742-53.
ჩამოტვირთვები
გამოქვეყნებული
როგორ უნდა ციტირება
გამოცემა
სექცია
